Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Biogen Inc.NASDAQ: BIIB
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q2 FY2026 EBITDA of $450.8M fell 59.4% year over year, behind the -42.2% change in trailing-twelve-month EBITDA. Sequentially, it fell 27.5% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- EBITDA amounted to 30.0% of revenue in FY2025, down 0.9 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 26 analysts of $3.04B (+3.3%) for the fiscal year ending Dec 2026, a step up from the -1.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $450.8M-27.5% QoQ
- Last fiscal yearDec 2025
- $2.95B-1.7% YoY
- LTMJun 2026
- $1.96B-42.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.4% | -19.8% | +39.6 pp |
| 1 year | -1.7% | +3.3% | +5.0 pp |
| 3-year CAGR | -5.9% | +9.6% | +15.5 pp |
| 5-year CAGR | +6.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 2.95B USD
- Year-over-year change
- -1.7%
- 4-year CAGR
- -6.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.95B | -1.7% |
| FY2024 | 2024-12-31 | 3B | +26.0% |
| FY2023 | 2023-12-31 | 2.38B | -32.8% |
| FY2022 | 2022-12-31 | 3.54B | -9.9% |
| FY2021 | 2021-12-31 | 3.92B | — |
EBITDA vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 EBITDA of $1.96B is the 7th highest of the 11 companies compared; the peer median is $5.31B.
- Its year-over-year change of -42.2% is the 9th highest of 11, against a peer median of +5.2%.
- EBITDA amounts to 19.7% of revenue for BIIB, versus a peer median of 37.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.3B | +103.7% | +54.1% | 54.4% | |
| LTM Sep 2026 | $21.37B | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | $13.49B | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | $5.75B | +6.1% | +3.4% | 37.0% | |
| LTM Sep 2026 | $4.86B | +4.3% | +3.1% | 37.4% | |
| LTM Jun 2026 | $1.96B | -42.2% | -5.9% | 19.7% | |
| LTM Jun 2026 | $1.68B | -2.3% | +20.5% | 53.1% | |
| LTM Jun 2026 | $1.15B | +773.6% | — | 24.0% | |
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| Peer median (excluding BIIB) | $5.31B | +5.2% | +11.6% | 37.2% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.98B | 10.17B | 9.84B | 9.68B | 9.81B |
| Cost of Revenue | 2.11B | 2.28B | 2.53B | 2.31B | 2.9B |
| Gross Profit | 8.87B | 7.9B | 7.3B | 7.37B | 6.91B |
| Gross Margin | 80.8% | 77.6% | 74.2% | 76.1% | 70.5% |
| Research & Development | 3.4B | 2.6B | 2.7B | 2.49B | 1.95B |
| Selling, General & Admin | 2.68B | 2.41B | 2.5B | 2.39B | 2.43B |
| Operating Expenses | 6.08B | 5.01B | 5.2B | 4.88B | 5.04B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| EBITDA | 3.92B | 3.54B | 2.38B | 3B | 2.95B |
| EBITDA Margin | 35.7% | 34.8% | 24.2% | 31.0% | 30.0% |
| Operating Income | 2.79B | 2.89B | 2.1B | 2.49B | 1.88B |
| Operating Margin | 25.4% | 28.4% | 21.3% | 25.7% | 19.1% |
| Interest Income | 11M | 89.3M | 276.5M | 67.6M | 87.8M |
| Interest Expense | 253.6M | 246.6M | 246.9M | 250.3M | 246M |
| Other Income / Expenses | (1.01B) | 705.3M | (800.5M) | (584.3M) | (476M) |
| Income Before Tax | 1.78B | 3.59B | 1.3B | 1.91B | 1.4B |
| Pre-Tax Margin | 16.2% | 35.3% | 13.2% | 19.7% | 14.3% |
| Income Tax Expense | 52.5M | 632.8M | 135.3M | 273.8M | 108.11M |
| Net Income | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B |
| Net Margin | 14.2% | 29.9% | 11.8% | 16.9% | 13.2% |
| EPS (Basic) | 10.44 | 20.97 | 8.02 | 11.20 | 8.85 |
| EPS (Diluted) | 10.40 | 20.87 | 7.97 | 11.19 | 8.83 |
| Weighted Avg Shares | 149.1M | 145.3M | 144.7M | 145.7M | 146.7M |
| Weighted Avg Shares (Diluted) | 149.6M | 146M | 145.6M | 145.9M | 146.7M |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.